B-chronic lymphocytic leukemia (CLL) patients frequently suffer from moderate to severe hypogammaglobulinemia. This complication is a serious cause of morbidity and mortality in this disorder. There is recent evidence that natural killer (NK) cells modulate B-cell immunoglobin (Ig) synthesis/secretion. The authors therefore evaluated the circulating NK cells from B-CLL patients on their ability...

B-chronic lymphocytic leukemia (B-CLL)/Small lymphocytic lymphoma (SLL) is a neoplastic, lymphoproliferative disease, characterized by accumulation of small, mature lymphocytes of the Bcell line in the blood, bone marrow and lymphoid tissues. CLL and SLL are different manifestations of the same disease. The major difference is that in CLL a significant number of the abnormal lymphocytes are als...

In chronic lymphocytic leukemia (CLL) the proliferation rate and resistance to drug-induced apoptosis are recognized as important factors in the outcome of treatment. In this study, we assess the activity and the mechanism of action of the prototype cell division cycle kinase 7 (Cdc7) inhibitor, PHA-767491, which inhibits the initiation of DNA replication but also has cyclin-dependent kinase 9 ...

Chronic lymphocytic leukemia/small lymphoma (CLL/SLL) is characterized by the accumulation of abnormal lymphocytes in blood, bone marrow, and lymphoid tissues, leading to a weakened immune system an increased risk infections for patients. The NCCN Guidelines CLL/SLL underscore need comprehensive evaluation multiple factors determine most appropriate treatment approach each patient. For frontlin...

Several miRNAs have been reported to be associated with immunoglobulin heavy chain (IgH) mutation and ZAP-70 expression status in blood samples of B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma (B-CLL/SLL). In the bone marrow and lymphoid tissues, proliferation centres (PCs) represent an important site of activation and proliferation of the neoplastic cells, suggesting that the...

Russian Academy of Medical Sciences, 4 Novyi Zykovski Proezd, Moscow 125167, Russia Tel 7 495 612 51 71 Fax 7 495 612 51 71 Email [email protected] Abstract: Recent studies of chronic lymphocytic leukemia (CLL) show that malignant B cells proliferate at a rate similar to normal B lymphocytes. This is in apparent contradiction to the very low proliferation rate found in blood specimens from CL...

Background: A subgroup of T and B cells express the extracellular enzyme cluster differentiation (CD73), which hydrolyzes adenosine monophosphate to adenosine. This work aimed evaluate CD73 expression its correlation with other disease characteristics in leukemia chronic lymphocytic type (CLL) patients. Methods: cross-sectional research was done on 30 CLL cases diagnosed by laboratory investiga...

I read with great interest a report by OBrien et all in a recent issue of Blood in which results on a large series of chronic lymphocytic leukemia (CLL) patients treated at the M.D. Anderson Cancer Center with a combination of fludarabine and prednisone have been presented. As stated in the report, although this combination “has significant activity in CLL, the response rates were no higher tha...

Background: Hypocholesterolemia possibly due to increased demand and uptake is correlated with elevated cancer risk mortality. However, hardly any current prognostic factor or model for chronic lymphocytic leukemia (CLL) established on reprogramed lipid metabolism, which suggests the importance of nutritional status tumor metabolism during leukemogenesis has been neglected. Our study aims inves...

BACKGROUND Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respond poorly to first-line chemoimmunotherapy, resulting in early relapse and short survival. We investigated the safety and activity of ibrutinib in previously untreated and relapsed or refractory CLL with TP53 aberrations. METHODS In this investigator-initiated, single-arm phase 2 study, we enrolled eligibl...